U.S. FDA Had 12 Issues With Wockhardt's Sole U.S. Plant, Report Says
This article was originally published in PharmAsia News
The U.S. FDA said its problems with Wockhardt's Chicago-area drug-production plant involve quality, hygiene and training problems, all issues cited for putting import bans on the drug maker's India plants.
You may also be interested in...
Experts think GLP-1s in neurodegeneration may be Novo Nordisk’s next opportunity and await readouts from the Phase II ELAD trial in Alzheimer's disease for signals.
France has announced a number of emergency measures to protect drug supplies threatened by the spread of the coronavirus.
Major generics companies have donated hydroxychloroquine sulfate doses for research and treatment of coronavirus. Companies are also donating hand sanitizer and personal protective equipment and are preparing to ramp up manufacturing and production.